GB201802326D0 - Gene therapy - Google Patents

Gene therapy

Info

Publication number
GB201802326D0
GB201802326D0 GBGB1802326.7A GB201802326A GB201802326D0 GB 201802326 D0 GB201802326 D0 GB 201802326D0 GB 201802326 A GB201802326 A GB 201802326A GB 201802326 D0 GB201802326 D0 GB 201802326D0
Authority
GB
United Kingdom
Prior art keywords
gene therapy
therapy
gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1802326.7A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UCL Business Ltd
Original Assignee
UCL Business Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UCL Business Ltd filed Critical UCL Business Ltd
Priority to GBGB1802326.7A priority Critical patent/GB201802326D0/en
Publication of GB201802326D0 publication Critical patent/GB201802326D0/en
Priority to PCT/GB2019/050368 priority patent/WO2019158909A1/en
Priority to CA3090617A priority patent/CA3090617A1/en
Priority to EP19708599.6A priority patent/EP3752608B1/en
Priority to CN201980025731.2A priority patent/CN112088214A/zh
Priority to JP2020542955A priority patent/JP2021512929A/ja
Priority to AU2019221798A priority patent/AU2019221798A1/en
Priority to US16/969,278 priority patent/US12241066B2/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • C12N9/80—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in linear amides (3.5.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/01—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in linear amides (3.5.1)
    • C12Y305/01004—Amidase (3.5.1.4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
GBGB1802326.7A 2018-02-13 2018-02-13 Gene therapy Ceased GB201802326D0 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
GBGB1802326.7A GB201802326D0 (en) 2018-02-13 2018-02-13 Gene therapy
PCT/GB2019/050368 WO2019158909A1 (en) 2018-02-13 2019-02-12 Gene therapy of the faah pseudogene
CA3090617A CA3090617A1 (en) 2018-02-13 2019-02-12 Gene therapy of the faah pseudogene
EP19708599.6A EP3752608B1 (en) 2018-02-13 2019-02-12 Gene therapy of the faah pseudogene
CN201980025731.2A CN112088214A (zh) 2018-02-13 2019-02-12 Faah假基因的基因疗法
JP2020542955A JP2021512929A (ja) 2018-02-13 2019-02-12 Ｆａａｈ偽遺伝子の遺伝子療法
AU2019221798A AU2019221798A1 (en) 2018-02-13 2019-02-12 Gene therapy of the faah pseudogene
US16/969,278 US12241066B2 (en) 2018-02-13 2019-02-12 Gene therapy of the FAAH pseudogene

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1802326.7A GB201802326D0 (en) 2018-02-13 2018-02-13 Gene therapy

Publications (1)

Publication Number Publication Date
GB201802326D0 true GB201802326D0 (en) 2018-03-28

Family

ID=61731413

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1802326.7A Ceased GB201802326D0 (en) 2018-02-13 2018-02-13 Gene therapy

Country Status (8)

Country Link
US (1) US12241066B2 (https=)
EP (1) EP3752608B1 (https=)
JP (1) JP2021512929A (https=)
CN (1) CN112088214A (https=)
AU (1) AU2019221798A1 (https=)
CA (1) CA3090617A1 (https=)
GB (1) GB201802326D0 (https=)
WO (1) WO2019158909A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022018638A1 (en) 2020-07-21 2022-01-27 Crispr Therapeutics Ag Genome-editing compositions and methods to modulate faah for treatment of neurological disorders
WO2022020756A1 (en) * 2020-07-23 2022-01-27 John Mansell Compositions and methods for treating pain and anxiety disorders
CN119932015B (zh) * 2024-12-20 2025-11-25 中国科学院生物物理研究所 一种lncATRIG抑制剂及其在制备治疗胶质瘤的药物中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7541359B2 (en) 2005-06-30 2009-06-02 Janssen Pharmaceutica N.V. N-heteroarylpiperazinyl ureas as modulators of fatty acid amide hydrolase
US20070088073A1 (en) * 2005-10-19 2007-04-19 Allergan, Inc. Method for treating pain
US9920317B2 (en) * 2010-11-12 2018-03-20 The General Hospital Corporation Polycomb-associated non-coding RNAs
EP2670245B1 (en) 2011-02-04 2015-09-09 The Scripps Research Institute Alpha-ketoheterocycles and methods of making and using
KR102079404B1 (ko) 2011-08-19 2020-02-19 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 메타-치환된 비페닐 말초 제한형 faah 억제제

Also Published As

Publication number Publication date
CN112088214A (zh) 2020-12-15
US20210002648A1 (en) 2021-01-07
EP3752608B1 (en) 2026-03-18
EP3752608A1 (en) 2020-12-23
JP2021512929A (ja) 2021-05-20
US12241066B2 (en) 2025-03-04
WO2019158909A1 (en) 2019-08-22
AU2019221798A1 (en) 2020-09-03
CA3090617A1 (en) 2019-08-22

Similar Documents

Publication Publication Date Title
HUE069690T2 (hu) Génterápia
GB201804255D0 (en) Macrophage-based therapy
PL3262066T3 (pl) Terapia genowa
HUE056570T2 (hu) Génterápia
GB201900702D0 (en) Therapy
IL279685A (en) Gene therapy
GB201905301D0 (en) Gene therapy
GB201819853D0 (en) Therapy
ZA202100244B (en) Combinatorial gene therapy
GB201707212D0 (en) Gene therapy for ciliopathies
GB201802326D0 (en) Gene therapy
GB201701968D0 (en) Gene therapy
IL275613A (en) Gene therapy for eosinophilic disorders
GB201817470D0 (en) Gene therapy
GB201817385D0 (en) Therapy
GB201818579D0 (en) New therapy
GB201814036D0 (en) New therapy
GB201820982D0 (en) Gene Therapy
GB201811541D0 (en) Gene therapy
GB201801511D0 (en) Gene therapy
GB201919036D0 (en) Therapy
GB201916983D0 (en) Therapy
GB201914848D0 (en) Therapy
GB201913797D0 (en) Therapy
GB201913785D0 (en) Therapy

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)